More on SVRA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.45 |
|
|||
| Open | $4.53 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $4.62 | ||||
| Day Low | $4.50 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 361,904 | ||||
- Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
- JPMorgan Starts Savara (SVRA) at Overweight
- Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism
- Form 4 Savara Inc For: Sep 24 Filed by: Parker Braden C.
- Increasing unusual call option volume: BBD SVRA SGHC ABUS XP U GDDY ACAD AUPH TSSI LTH
- Savara to present IMPALA-2 trial data at ERS Congress in Barcelona
- Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
- Savara Announces New Employment Inducement Grant
- Form SCHEDULE 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
- Form S-8 Savara Inc
Entities mentioned with SVRA
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Show More...
